Posted: 2 September 2024 BioMelbourne Network has opened nominations for its Women in Leadership Awards 2025. This prestigious event, now in its 11th year, continues to recognise and champion women who have made outstanding contributions in the healthtech…
Posted: 28 August 2024 Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or…
Posted: 28 August 2024 GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’…
Posted: 28 August 2024 Australians diagnosed with a type of metastatic breast cancer will now have access to a life prolonging treatment under the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. Trastuzumab deruxtecan (Enhertu®) will be expanded on…
Posted: 28 August 2024 With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical…
Posted: 28 August 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises it has received the first batch of the Alpha version of the multiplex antibody detection kits developed and…
Posted: 27 August 2024 Lumos Diagnostics (ASX:LDX) has extended its existing deal with the Burnet Diagnostics Initiative to progress a new point-of-care test for use in monitoring liver health in an upcoming clinical trial. As part of the deal,…
Posted: 27 August 2024 In a world first, a new wearable device developed by Monash University researchers will help to record the impact of artificial light on our bodies for sound sleep, improved mental wellbeing and treating chronic…
Posted: 27 August 2024 An international collaboration, involving researchers from Monash University and the University of Oxford, has led to a breakthrough in our understanding of how immune responses are started. The study has just been published in Nature. The human…
Posted: 27 August 2024 Quantum sensors that will revolutionise diagnosis and management of iron disorders, move to its next phase, thanks to AEA funding. An estimated 1 in 5 women (and 1 in 20 men) in Australia are…
Posted: 22 August 2024 Amplia Therapeutics Limited is pleased to announce that a fifth patient enrolled in the Company’s Phase 2a clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30% or greater decrease…
Posted: 22 August 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce its first in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial is planned to start in early calendar year 2025…